| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abf1f0a2ba91ee72070a28b36dac7424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a20deb6fc4e659aadd0db7c41e13966 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_619ff577b8e1a5a13bd7f1088379f6bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c04a1d941bcf64bba25065bd4d570119
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7113b5ba80886f638afad0a345aa401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2da80b6004b09c67c425756af5605868 |
| publicationDate |
2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11291672-B2 |
| titleOfInvention |
Betamethasone oral spray formulation and method of use to treat ataxia |
| abstract |
A stable oral spray formulation comprising a glucocorticoid together with other excipients is disclosed. In preferred embodiments, the spray formulation is used to treat neurological disorders such as ataxia by being sprayed in an effective dose into the mouth of a patient. |
| priorityDate |
2016-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |